However, the frequency of BRAF and NRAS mutations in acral melanoma is considerably lower than that in cutaneous melanoma, leaving most acral melanoma patients ineligible for treatment with BRAF inhibitors and the combination of BRAF/MEK inhibitors (13, 46). Here, NRAS is linked to cutaneous melanoma.